Redcliffe Lifetech raises $61 million in Series B

According to Dheeraj Jain, founder of Redcliffe Lifetech, preventative medicine aims to empower the common Indians with the information they need to take care of their health and welfare. "Redcliffe has created a one-stop diagnostic shop, offering a wide range of tests and bringing treatment closer to the client." This investment will help us scale

Redcliffe Life Sciences, located in New Delhi, announced a *$61 million funding round led by LeapFrog Investments on Friday (LeapFrog).

Other investors in the round included Healthquad, Schroders, LC Nueva, and Growth Spark Ventures, as well as current investors Chiratae Ventures and Alkemi Venture Partners.

The startup raised $10 million in its Series A fundraising round last year.

The diagnostic platform will utilize the funding to extend its low-cost but high-quality direct-to-consumer diagnostics into Tier-II, III, and IV cities, providing affordable, speedy, and accessible pathology services to millions of households.

According to Dheeraj Jain, founder of Redcliffe Lifetech, preventative medicine aims to empower the common Indians with the information they need to take care of their health and welfare. "Redcliffe has created a one-stop diagnostic shop, offering a wide range of tests and bringing treatment closer to the client." This investment will help us scale to fulfil our aim of reaching over 500 million Indians in the next five years,"

Redcliffe will also use the funds to extend its platform and expand its product offerings including radiography, illness data profiling, and lifestyle management in an attempt to reform India's healthcare focus from treatment to early diagnosis and prevention.

Across 14 cities, Redcliffe Diagnostics operates 22 state-of-the-art labs.

Its unique omnichannel infrastructure — which combines an online channel with a fleet of 400 phlebotomists operating in 100+ cities with home sample collection and an offline network of 500 collection centers — enables the company to offer over 3,500 different pathology and highly specialized tests, including genetics at affordable prices around 25-60 percent less than traditional competitors.

The company's current annualized sales run rate, according to Jain, is approximate $55- $60 million.
Redcliffe's low-cost diagnostics are intended to help reduce the burden of noncommunicable diseases (NCDs), such as heart disease, cancer, and diabetes, which harm over six million Indians each year.

Tags : #fundingalert #funding #investments #investors #redcliffe #diagnostics #indianstartups #startupfunding #healthcare #healthcarestartups #dheerajjain #smitakumar #medicircle

About the Author


Team Medicircle

Related Stories

Loading Please wait...

-Advertisements-




Trending Now

Broad-Spectrum RNA Vaccine Breakthrough for Enhanced Virus ProtectionApril 17, 2024
The Impact of Excessive Internet Usage on School Absence: Finnish Study Reveals Key FindingsApril 17, 2024
Uncovering Delhi's Illegal Fertility Centre Operations: Insights from Recent Child Trafficking CasesApril 17, 2024
Emergency Healthcare Provider Medulance Secures $3 Million Series A Funding Led by Alkemi Growth CapitalApril 16, 2024
The Healing Power of Natural Diversity: How Nature Boosts Mental HealthApril 16, 2024
Unveiling Cellular Recycling: How Nutrient-Starved Cells Adapt to Stressful ConditionsApril 16, 2024
Advancing Cancer Care: AIIMS Bhopal’s Workshop on Biomarker Interpretation in Breast CancerApril 15, 2024
10 Powerful Benefits to Diversify Healthcare Advertising ChannelsApril 15, 2024
Understanding Hospital Sink Contamination: Challenges in Fighting Multidrug-Resistant BacteriaApril 15, 2024
Rajasthan’s Swine Flu Situation: Health Department Observes DeclineApril 15, 2024
Is Your Doctor’s Prescription Incomplete ? Insights from Recent ICMR Study Suggests So!April 13, 2024
Ministry of Health Dispels Misinformation on Medicine Price Surge from April 1April 13, 2024
India’s First Indigenous CAR T-Cell Therapy Launched By President Droupadi Murmu: A New Hope in Cancer TreatmentApril 12, 2024
Investigation Launched After Cataract Surgery Patients Experience Side-Effects in IndoreApril 12, 2024
The Reality of Protein Supplements in India: Mislabeling, Toxins, and Quality ChallengesApril 12, 2024
A Majority Of People Are Piling Up Weight Despite Adhering To A Healthy Lifestyle, Opt For These Vital Tests: ExpertsApril 11, 2024
Fighting Tuberculosis: IHLD and Krafton India Join Forces for Active Case DetectionApril 11, 2024
ICMR Study Reveals Blood Pressure Monitoring Gaps in IndiaApril 11, 2024
Innovative Procedure at KGMU Saves Man Impaled by Iron Rod: Beating Heart Surgery SuccessApril 11, 2024
Heart-Healthy Choices: How Salt Substitutes Can Prolong Your LifeApril 11, 2024